Anthos CEO On When Big Promo Efforts Are Needed, Telehealth's Acute Care Promise

Pandemic Catalyses Shifting Practices

07 Sep 2021

Anthos Therapeutics’ CEO and ex-head of global commercial operations at Novartis Pharma, John Glasspool, says there’s no "automatic premise" that the large promotional launch model is broken. He also outlines how teleconsultation is taking medicine back to its roots and "where it can be" as well, with patients less likely to get white coat syndrome.

launch — Launch Promotional Models Won't Always Be Small And Tailored • Source: Alamy

A digitally tailored, cost-efficient commercialization approach, especially for smaller biopharma firms, may be the buzz in COVID-19 times. But the big promotional launch model, with a sizable face-to-face component, is still the way to go for some novel and transformational therapies, a top industry executive indicated to In Vivo.

John Glasspool, CEO of Anthos Therapeutics Inc., a clinical-stage biopharmaceutical firm backed by PE Blackstone Life Sciences, said that...